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patient subsequently reported that her 
stuttering had ceased.
A high degree of clinical 
suspicion for WNV infection should 
be considered in patients with a recent 
history of mosquito bites and an 
acute febrile illness associated with 
neurologic signs and symptoms (5). 
Typical CSF fi ndings of infection 
with WNV include lymphocytic 
pleocytosis, elevated protein level, 
reference glucose and lactic acid 
levels, and no erythrocytes (6).
The clinical presentation of 
WNV infection varied widely from 
asymptomatic seroconversion to fatal 
encephalitis. It is possible, but unlikely, 
that the stuttering in the patient was an 
indication of a migraine aura. Initially, 
the patient reported that the headache 
might have been a migraine, but later 
reported that its associated symptoms, 
e.g., photophobia, were not as severe 
and did not last as long as her usual 
migraines. Further argument against 
migraine aura is the lack of response 
to her migraine medication and the 
fact that the stuttering continued after 
the headache resolved.
Because WNV resembles JEV, 
it is interesting to note that a case of 
stuttering in a young adult infected 
with JEV has been reported (7). 
However, the mechanism of stuttering 
associated with WNV is unknown. 
One possible explanation is myoclonic 
contractions of the tongue, i.e., vocal 
myoclonus.
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No Evidence of 
Dengue Virus 
Circulation in Rural 
Gabon
To the Editor: Dengue virus 
(DENV) is a mosquito-borne 
RNA virus belonging to the family 
Flaviviridae. It is composed of 4 
closely related serotypes designated 
DENV-1–4. There are 2 transmission 
cycles for this virus. The endemic/
epidemic cycle involves humans and 
the mosquito species Aedes aegypti 
and Ae. albopictus. The zoonotic or 
sylvatic cycle involves monkeys and 
sylvatic Aedes spp. mosquitoes (1).
Despite occasionally severe 
clinical forms, human dengue 
usually consists of a self-limited 
febrile disease often associated with 
asthenia, headache, rash, arthralgia, 
and myalgia. DENV is widely 
distributed throughout Asia, the 
Pacifi c, Central and South America, 
the Middle East, and Africa (2,3). In 
Africa, most DENV outbreaks have 
been reported in the eastern regions, 
and episodic cases have occurred in 
western regions. However, few data 
are available for central regions.
In Gabon, concurrent of trans-
mission of DENV and chikungunya 
virus was documented in 2007 during 
a large outbreak of dengue (4). This 
outbreak affected Libreville and major 
cities in northwestern Gabon and was 
caused by DENV-2. DENV isolates 
were closely related to strains from 
Asia, suggesting that the outbreak 
resulted from recent introduction of 
the virus. Epidemic DENV strains are 
constantly moving from one region to 
another, and local DENV transmission 
from sylvatic to urban areas has been 
documented in some countries in 
Africa (5,6).
To examine possible circulation 
of DENV in Gabon, we tested the 
following for antibodies against 
dengue: villagers living in rural areas, 
pet monkeys in the same areas, and 
wild monkeys killed in forests for 
bushmeat. A total of 4,341 persons and 
186 pet monkeys were sampled during 
July 2005–May 2008 in 220 randomly 
selected villages, which represented 
10.3% of all villages in Gabon. Fifty 
wild monkeys were also sampled 
during October 2009–August 2010 in 
different regions of Gabon (Table).
DENV-specifi c immunoglobulin 
(Ig) G and IgM were detected by using 
capture ELISA kits (Panbio; Brisbane, 
Queensland, Australia) (7) according 
the manufacturer’s instructions. All 
samples were tested with an IgG 
assay, which was designed to detect 
high antibody titers usually associated 
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with secondary dengue infection. 
All IgG-positive human samples, 
910 randomly selected IgG-negative 
human samples, and all monkey 
samples were also tested by using an 
IgM capture ELISA.
In humans, overall prevalences 
of DENV-specifi c IgG and IgM were 
0.5% (20/4341) and 0.5% (5/930), 
respectively, and only 1 of 20 IgG-
positive samples was IgM positive. 
No IgG or IgM against DENV was 
detected in pet or wild monkeys. 
Although the IgG capture ELISA 
did not enable us to detect low and 
medium titers, absence of IgM and IgG 
against DENV in pet and bushmeat 
monkeys indicates a lack of recent 
or secondary infections. In humans, 
the low prevalences of IgM and IgG 
against DENV suggest that DENV 
does not circulate actively in rural 
Gabon, although the 2 assays do not 
detect late primary DENV infection.
Although these ELISAs have 
been extensively validated (diagnostic 
sensitivity of 98.6% and specifi city 
of 99.4%) (7), some of our samples 
may have shown false-positive results 
because IgG cross-reactivity between 
fl aviviruses can occur (8). The rare 
serum specimen positive for IgG 
against DENV may also indicate a 
low level of DENV circulation in rural 
Gabon, or may be related to travel 
to and from neighboring countries. 
After the outbreak in Gabon, DENV 
surveillance with active detection 
of febrile human cases is needed to 
determine whether this virus will 
become endemic to this area.
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Table. Prevalence of IgG and IgM against dengue virus in humans and nonhuman primates, Gabon* 
Province
No. positive/no. tested (% positive) 
Humans Pet monkeys† Wild monkeys‡ 
IgG IgM IgG IgM IgG IgM
Estuaire 5/286 (1.7) 1/95 (1.1) 0/13 (0) 0/13 (0) 0/1 (0) 0/1 (0) 
Haut-Ogooué 1/364 (0.3) 0/80 (0) 0/8 (0) 0/8 (0) 0/1 (0) 0/1 (0) 
Moyen-Ogooué 3/558 (0.5) 1/113 (0.9) 0/10 (0) 0/10 (0) 0/7 (0) 0/7 (0) 
Ngounié 0/146 (0) 0/60 (0) 0/51(0) 0/51 (0) 0/5 (0) 0/5 (0) 
Nyanga 1/774 (0.1) 0/151 (0) 0/33 (0) 0/33 (0) 0/2 (0) 0/2 (0) 
Ogooué Ivindo 5/499 (1) 0/105 (0) 0/31(0) 0/31 (0) 0/3 (0) 0/3 (0) 
Ogooué-Lolo 0/416 (0) 0/90 (0) 0/11 (0) 0/11 (0) 0/3 (0) 0/3 (0) 
Ogooué-Maritime 2/197 (1) 1/72 (1.4) 0 0 0/18 (0) 0/18 (0) 
Woleu-Ntem 3/831 (0.4) 2/163 (1.2) 0/29 (0) 0/29 (0) 0/10 (0) 0/10 (0) 
Total 20/4,341 (0.5) 5/930 (0.5) 0/186 (0) 0/186 (0) 0/50 (0) 0/50 (0) 
*Ig, immunoglobulin. 
†Cercopithecus cephus, C. nictitans, C. neglectus, C. pogonias, C. solatus, Cercocebus torquatus, Gorilla gorilla, Lophocebus albigena, Mandrillus 
sphinx, Miopithecus ogoouensis, and Pan troglodytes species. 
‡Cercopithecus cephus, C. nictitans, C. neglectus, C. pogonias, Cercocebus torquatus, Mandrillus sphinx, and Perodictitus potto species. 
